Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. - Wikidata - awgldk - TriplyDB

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

http://www.wikidata.org/entity/Q30424687

about

Interventions for preventing the progression of autosomal dominant polycystic kidney disease Experimental therapies and ongoing clinical trials to slow down progression of ADPKD Regulation of nephron water and electrolyte transport by adenylyl cyclases The role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies Hyponatremia in cirrhosis: pathophysiology and management An Empirical Biomarker-Based Calculator for Cystic Index in a Model of Autosomal Recessive Polycystic Kidney Disease-The Nieto-Narayan Formula Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease Successful treatment with tolvaptan to control blood volume and hyponatremia in a chronic kidney disease patient.Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again.Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?Hyponatremia: A practical approach.Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model Neurosurgical Hyponatremia Renal disease progression in autosomal dominant polycystic kidney disease Technical Evaluation: Identification of Pathogenic Mutations in PKD1 and PKD2 in Patients with Autosomal Dominant Polycystic Kidney Disease by Next-Generation Sequencing and Use of a Comprehensive New Classification System.Effect of tolvaptan on renal water and sodium excretion and blood pressure during nitric oxide inhibition: a dose-response study in healthy subjects Insignificant effect of secretin in rodent models of polycystic kidney and liver disease.Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort Heterotrimeric G protein signaling in polycystic kidney disease Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function.Polycystic kidney disease in 2011: Connecting the dots toward a polycystic kidney disease therapy.Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment.Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies.Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease.Vasopressin: a novel target for the prevention and retardation of kidney disease?New treatments for autosomal dominant polycystic kidney disease Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.Pharmacological management of polycystic kidney disease.Review of tolvaptan for autosomal dominant polycystic kidney disease.Effects of dietary interventions on incidence and progression of CKD.Vasopressin regulation of sodium transport in the distal nephron and collecting duct.An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease.Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach.Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?Age-Related Alterations in Blood Biochemical Characterization of Hepatorenal Function in the PCK Rat: A Model of Polycystic Kidney Disease.CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD.

P2860

Q24186484-FCE56247-1A45-42ED-A2F1-285921B9C2CA Q27001230-795E421A-F745-412A-9FE9-032AD9056F3B Q27023655-394BFE21-C98F-4D7E-8162-A303C68ADCC4 Q27026481-3A183498-1599-4CE2-9E98-9B9CE8DA64FC Q27027861-DD19618F-ABEB-447D-9171-19849B264F1D Q28554449-AFF79F6E-09B6-48BC-92BC-394C8D9F76DF Q29037884-AE303233-50E0-4F77-90BA-DC87EFDAABE5 Q33622094-EAD16234-E292-4222-9EEB-0C7BEDCAA1EE Q33660700-19E17F07-788F-4BC6-828A-CDCD0822DDE1 Q33702355-B38CF706-D092-4735-A401-CC381A0F094F Q34094366-5643616F-2BBD-4827-BC52-1789F08E5A61 Q34319649-EB145EC6-9D59-4CE8-84C7-0051612ED757 Q34423262-8982FE73-852B-45CE-B765-5ACC886DFEB7 Q34787786-BF937C01-9F13-4A9A-8A62-DBD265EFCF98 Q35750524-5E4D644A-C964-44D3-B559-5A871EFD32CC Q36157451-B5CC1104-884A-4CD8-8BB3-72DABF1A535E Q36189869-8DD03901-067B-4E01-9929-0EC83D98E979 Q36306545-836100EA-71AA-4032-BBEF-A8DE91CB1CC0 Q36312676-FEC50D35-91D3-4A5C-B375-A7A9280E1157 Q36357916-B44A7293-8942-4794-B29C-9A96BFEA37AB Q36616057-F67F801F-AE89-4CF7-BFC2-83C971711CE7 Q37139683-272FF6C3-0A42-4F50-9467-7670AF221515 Q37679896-8B8FA16C-F638-487B-B531-B29652192B73 Q37967082-92510F56-4089-4585-9016-A3022580ABB3 Q38030726-FFFC787F-B741-4AF3-87D5-16B6B61D3734 Q38063460-9EC213F3-4CE6-4B5A-A737-CAE968F2DAE3 Q38067358-7044A2B4-6F99-4378-8DF3-626149F5FC60 Q38084471-4438DB52-ABAA-445C-8B96-DC9AEC9CD94E Q38099698-3A1216B9-AE3E-446E-8B10-708AF12C8799 Q38171193-2A161F04-8F5D-46A9-9763-B124B6510AFB Q38199755-4EE083C1-344B-4459-BD17-1A2D0CACF9B1 Q38202613-F8B72264-8279-456C-B062-9FED071A2CEE Q38261585-E72D909A-657E-4768-B836-09454542C12E Q38515104-2E0297F5-D1D0-45EF-87EF-FCC5181B8980 Q38540557-B794D8B6-2E11-49BD-8F13-9AD1E9F66766 Q38593001-4C201B73-9AF7-43D9-8943-AC596724034C Q39304722-A08068D4-0FD6-4251-952D-217DF920732C Q40386706-B5167575-B64C-49E0-9DE3-D6988BAF12F3 Q40390494-65B562BF-EF3A-47ED-8459-7CB948E8D1C0 Q41787735-7B6C5D12-CCC8-4A13-90C1-2C64B83BEFFA

P2860

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

http://www.wikidata.org/entity/Q30424687

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

@ast

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

@en

type

label

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

@ast

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

@en

prefLabel

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

@ast

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

@en

P1433

Q30424687-D52CC83B-8770-46C2-A0F3-32A15E976E2D

P1476

Q30424687-FF1608A9-996E-4DD4-B257-D8BC712398CA

P2093

Q30424687-473741D2-55F8-4CAD-AB2E-3DF1564EAEB1

Q30424687-498C72E8-44CF-4E63-BACD-78EC1AB15A51

Q30424687-4C3F33F2-9238-435E-9EA8-5EF13938C872

Q30424687-505C696A-89A9-4347-BF6F-F972DECC710A

Q30424687-5C97E5A0-C7B6-4CD5-99E6-8F0A19B56E9C

Q30424687-70097645-2231-4ED0-A907-9F2CAC4C1E9B

Q30424687-899A61E4-1F02-4FF6-8594-87EB4BB48A40

Q30424687-C02AB9E4-65D0-4FF3-B90C-3C1B2CA7F906

Q30424687-C8A12B3D-7443-4D8F-A684-A81E189A5F43

Q30424687-D9CD4562-7767-43DD-A93B-D870CA2BF211

P2860

Q30424687-03F9BE12-D6E1-49E2-A51F-5D1AB2ABC33A

Q30424687-50356C04-A0D4-4BF0-97ED-99A4EB476C97

Q30424687-6F9F82AC-835C-45D3-B4D9-97CC16103FB6

Q30424687-82097D4D-C06D-4E6A-830E-3C11F6623AEF

Q30424687-90B16954-9E76-4783-A259-F6583817B983

Q30424687-A477F038-E826-4E69-85BD-D65F16C8722B

Q30424687-A6D162D5-BE18-4498-B891-FC103BBDF835

Q30424687-B07484FD-A226-4CD1-A42E-F61B73CE60C1

Q30424687-B6F0006C-81A9-4002-A3F0-20435DFB96B7

Q30424687-E5CE6BD7-B1CA-4C26-9960-637C768A6E19

P304

Q30424687-81AF35C8-36C6-4CFE-8CC6-5332105563FE

P31

Q30424687-37E20965-9C1A-487E-8403-49618C932CFD

P356

Q30424687-FC2E51E4-A027-4B12-883C-25003B08435E

P433

Q30424687-36E63B17-EA85-453C-9E09-ABD9B47B9197

P478

Q30424687-C3BE77AD-DCCC-41DA-8B4A-4ABF7F830356

P577

Q30424687-90E753CB-9F66-4B41-BC0E-E00F307391FD

P698

Q30424687-FAB43F18-7BBA-46D8-8A8C-437153D541B8

P921

Q30424687-6C5AAE92-BA7F-4F40-BFFC-043B8A9FC029

P932

Q30424687-B41FDF7F-A0E0-45C0-9C06-60F3D4C63605

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

@en

P2093

Arlene B Chapman

http://www.w3.org/2001/XMLSchema#string

Eiji Higashihara

http://www.w3.org/2001/XMLSchema#string

Frank S Czerwiec

http://www.w3.org/2001/XMLSchema#string

Holly B Krasa

http://www.w3.org/2001/XMLSchema#string

Jared J Grantham

http://www.w3.org/2001/XMLSchema#string

John Ouyang

http://www.w3.org/2001/XMLSchema#string

Kikuo Nutahara

http://www.w3.org/2001/XMLSchema#string

Kyongtae Bae

http://www.w3.org/2001/XMLSchema#string

Shigeo Horie

http://www.w3.org/2001/XMLSchema#string

TEMPOFormula and 156-05-002 Study Investigators

http://www.w3.org/2001/XMLSchema#string

P2860

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

Clinical practice. Autosomal dominant polycystic kidney disease.

Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families.

Pain management in polycystic kidney disease.

Water prescription in autosomal dominant polycystic kidney disease: a pilot study.

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.

Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.

Surrogate end points for clinical trials of kidney disease progression.

Vasopressin in chronic kidney disease: an elephant in the room?

Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates.

P304

2499-2507

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.03530411

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21903984

http://www.w3.org/2001/XMLSchema#string

P921

autosomal dominant polycystic kidney disease

P932

3359559

http://www.w3.org/2001/XMLSchema#string